Application of bee venom in anticancer therapy: study on human cervical and laryngeal carcinoma cells and their drug resistant sublines (CROSBI ID 578150)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Gajski, Goran ; Čimbora-Zovko, Tamara ; Rak, Sanjica ; Osmak, Maja ; Garaj-Vrhovac, Vera
engleski
Application of bee venom in anticancer therapy: study on human cervical and laryngeal carcinoma cells and their drug resistant sublines
Throughout history nature has provided a rich source of compounds used in medicine, including cancer therapy. One such product, bee venom derived from Apis mellifera, has been studied extensively over the past few years. We studied the effects of bee venom against tumour cells in vitro. For that purpose we used human cervical carcinoma HeLa and laryngeal carcinoma HEp-2 cells and their drug resistant sublines (HeLa CK and CK2 cells, respectively). After treatment, bee venom displayed toxic effect in all cell lines, which was evaluated using the MTT reduction assay. Bee venom also caused significant morphological changes, determined by light and fluorescent microscopy. Cells rounded, granulated, shrank, and eventually detached themselves from culture plates. Fast staining with ethidium bromide (within one hour of treatment) showed that bee venom induced the necrotic type of cell death. Accordingly, Western blot analysis did not show a cleavage of poly (ADP-ribose) polymerase (PARP). In a combined treatment with cisplatin, bee venom exhibited an additive effect to this highly effective anticancer drug, used for the treatment of a broad spectrum of malignant diseases. This could be useful from the point of minimizing cisplatin concentration during chemotherapy. Our results are in accordance with other available data on anti-proliferative and pro-death activity of whole bee venom and its constituents and speak in favour of its application in anticancer therapy.
Bee venom; Antitumor activity; Cytotoxicity; Human cervical carcinoma HeLa cells; Human laryngeal carcinoma HEp-2 cells
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
2011.
objavljeno
Podaci o matičnoj publikaciji
FIP 2011 abstract
Podaci o skupu
71st International Congress of FIP
poster
03.09.2011-08.09.2011
Hyderābād, Indija